Proteome profiling reveals early diagnostic biomarker candidates for colorectal cancer
Key Points
Promising novel biomarkers for early diagnosis are CA1 and SMPDL3A, indicating potential for clinical application.
The analysis supports the need for larger prospective trials to validate the clinical utility of these biomarkers.
Identification of biomarkers can enhance early colorectal cancer diagnosis, allowing for timely intervention.
Further validation is necessary, highlighting the importance of confirming these findings in larger cohorts.
Abstract
CA1 and SMPDL3A proteins are promising novel specific biomarkers for the early diagnosis of CRC. However, larger prospective trials are necessary to validate their clinical utility.